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SUMMARY. Studies of IL-28B genotype in patients with
hepatitis C virus (HCV) genotype 2/3 infection have
yielded conflicting results. The aim of this meta-analysis
was to obtain a pooled odds ratio (OR) of the impact of IL-
28B genotype on achieving sustained virologic response
(SVR) in patients with HCV genotype 2/3 infection treated
with pegIFN and ribavirin. A meta-analysis with a ran-
dom effects model was performed, and study heterogeneity
and publication bias were assessed. Forty-three percent of
the Caucasians (11 studies) and 86% of Asians (five stud-
ies) had the favourable IL-28B genotype. In Caucasians,
the pooled OR of SVR with the favourable IL-28B
genotype was 1.36 (95%CI: 0.98–1.88, P = 0.07) in all
patients and 1.55 (95%CI: 1.10–2.18, P = 0.01) in
patients treated with pegIFN and ribavirin for
24 weeks. In Asians, the pooled OR of SVR in patients
with the favourable IL-28B genotype was 1.99 (95%CI:
0.94–4.25, P = 0.07). The favourable IL-28B genotype
was also significantly associated with rapid virologic
response (RVR) in both groups (Caucasians: OR: 1.82,
95%CI: 1.12–2.96, P = 0.02; Asians: 2.39, 95%CI: 1.39–
4.11, P = 0.002), as well as the likelihood of an SVR in a
subgroup of 350 Caucasian patients without an RVR (OR:
3.29, 95%CI: 1.67–6.51, P = 0.001). The favourable
IL-28B genotype is a statistically significant predictor of
SVR and RVR in Caucasian patients treated with pegIFN
and ribavirin for 24 weeks. In contrast, the favourable IL-
28B genotype is associated with RVR, but not SVR in
Asian HCV genotype 2 patients.
Keywords: genetic polymorphisms, hepatitis C, peginterferon,
ribavirin, sustained virologic response.
INTRODUCTION
A single nucleotide polymorphism (SNP) upstream of the
interleukin 28B (IL-28B) gene is associated with hepatic
responsiveness to interferon therapy in hepatitis C virus
(HCV) genotype 1 patients [1]. The highly variable preva-
lence of the favourable IL-28B genotype in patients of vary-
ing ethnicity, in part, explains differences in the observed
sustained virologic response (SVR) rates. Although other
host, viral and treatment factors may influence a patient’s
chance of SVR, the favourable IL-28B genotype is the single
most important pretreatment predictor of achieving SVR
with peginterferon (pegIFN) and ribavirin therapy in geno-
type 1 patients [2]. In contrast, the association of IL-28B
and SVR in patients with HCV genotype 2/3 infection
remains unclear [3–5].
Although patients with HCV genotype 2/3 are more
responsive to pegIFN and ribavirin, up to 30% of treated
patients will not achieve SVR [6]. Furthermore, the new
direct acting antiviral agents (DAAs), boceprevir and tela-
previr, are not approved for the use in patients with HCV
genotype 2/3 infection [7]. As such, pegIFN and ribavirin
remain the only currently approved treatment for these
patients. This meta-analysis was undertaken to better
quantify the effect of the favourable IL-28B genotype on
achieving SVR after treatment with pegIFN and ribavirin
in patients with chronic HCV genotype 2/3 infection. In
addition, the effect of IL-28B on achieving a week 4 rapid
virologic response (RVR) as well as the impact of patient
ethnicity on SVR was evaluated.
MATERIALS AND METHODS
Literature search
A search of the MEDLINE, PUBMED and EMBASE computer
databases was performed of manuscripts published between
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aminotransferase; BMI, Body mass index; CI, Confidence interval;
DAA, Direct acting antiviral agent; HCV, Hepatitis C virus; HIV,
Human immunodeficiency virus; IL-28B, Interleukin 28B; OR,
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on; RVR, Rapid virologic response; SNP, Single nucleotide poly-
morphism; SVR, Sustained virologic response.
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January 2000 and January 2012, using the text words IL-
28B, IL28B, IL28 and interleukin 28. Additional electronic
and manual searches of abstracts presented at the Ameri-
can Association for the Study of Liver Diseases and Ameri-
can Gastroenterological Association meetings were
undertaken from 2007 to 2012. Finally, consultation with
expert hepatologists and recursive manual searches of ref-
erences from published studies were performed.
Study selection criteria
Criteria for study inclusion were as follows: (i) published
studies of IL-28B genotyping in adults with HCV genotype
2 or 3 infection; (ii) treatment with pegIFN and ribavirin
and (iii) a reported outcome of SVR. All published studies
were included regardless of sample size, but studies pub-
lished solely as abstracts were excluded due to a lack of
extractable data for SVR stratified by IL-28B genotype. The
following exclusion criteria were applied: (i) human immu-
nodeficiency virus (HIV) co-infection, (ii) prior liver trans-
plantation, (iii) use of DAAs and (iv) use of IL-28B SNPs
other than rs12979860 or rs8099917. After reviewing all
citations identified in the literature search, two investiga-
tors (AS, RF) independently applied these selection criteria
and extracted data. Any disagreements were resolved by
consensus.
Data extraction
All eligible studies were reviewed in an independent and
duplicate manner by both investigators (AS, RF). For each
study, the following data were collected: (i) Study: year,
location, design, publication status; (ii) Patient factors: num-
ber, mean age, baseline serum aspartate aminotransferase
(AST), baseline alanine aminotransferase (ALT), body mass
index (BMI) and percentage with diabetes mellitus, male
gender, treatment na€ıve and HIV co-infection; (iii) HCV
factors: HCV genotype, baseline HCV RNA level, number of
patients achieving RVR and SVR; (iv) Treatment factors:
duration of pegIFN and ribavirin, type of pegIFN, dose
reduction of antiviral medications, use of growth factors;
and (v) IL-28B: IL-28B SNP tested and number with each
IL-28B genotype who achieved RVR and SVR. Discrepan-
cies in data extraction were resolved by discussion between
the investigators.
IL-28B testing
The two IL-28B SNPs reported in the individual studies
were rs12979860 and rs8099917. The favourable geno-
type for rs12979860 is CC, while the unfavourable geno-
types are CT and TT. The favourable genotype for
rs8099917 is TT, while the unfavourable genotypes are
TG and GG.
Primary outcome
The primary outcome measure was achievement of SVR
after pegIFN and ribavirin treatment, defined as undetect-
able serum HCV RNA by polymerase chain reaction (PCR)
testing 24 weeks after treatment.
Secondary outcome
A secondary outcome measure was achievement of RVR
with pegIFN and ribavirin treatment, defined as an unde-
tectable serum HCV RNA at week 4.
Quality assessment
Study quality was assessed using an 8-item scoring system
based on previously validated tools that focused on study
Fig. 1 Study selection overview. From a total of 308
studies, 16 studies met the inclusion criteria.
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design, population homogeneity and potential study biases
[8,9]. High quality was defined by a score of 6
(Table 2).
Statistical analysis
The estimate of effect was a pooled odds ratio (OR) deter-
mined using the DerSimonian and Laird method for a ran-
dom effects model. Study heterogeneity was assessed by
the I2 test, with I2 > 50% suggesting substantial heteroge-
neity. Publication bias was assessed through the Harbord
and Peters tests. Influence analysis was performed to deter-
mine whether a single study exerted undue influence. Data
from the included studies were analysed separately by
patient race. Sensitivity and subgroup analyses were per-
formed based on treatment algorithm, prior treatment and
study quality score. All statistics were computed using
STATA 11.0 (StataCorp LP, College Station, TX, USA).
RESULTS
An initial search revealed 308 studies of IL-28B among
which 88 specifically evaluated virologic outcomes in trea-
ted patients An additional 63 studies were excluded due to
the inclusion of previously treated patients, acute HCV
infection, use of alternative IL-28B SNPs, use of DAAs,
inclusion of liver transplant recipients, combined ethnicities
or nongenotype 2/3 patients. Of the remaining 25 studies,
nine were excluded due to redundant study populations,
HIV co-infection or use of alternative treatment regimens,
leaving 16 studies in the current analysis (Fig. 1).
Caucasians with HCV genotype 2/3
SVR outcome
There were 11 studies of Caucasians with HCV genotype 2/3
[3,10–19]. Among 1599 patients, 43% had the favourable
Table 1 Summary of individual studies of IL-28B genotype included in the meta-analysis
Study N
Age
(mean)
Male
(%)
BMI
(kg/m2)
Advanced
fibrosis (%)*
Treatment
duration
(weeks)
Prevalence of
favorable
IL-28B
genotype (%)
SVR in
favorable
IL-28B
genotype
(%)
SVR in
unfavorable
IL-28B
genotype (%)
Caucasian
Stattermayer
(Austria)
208 39 60 n/a 89 24 42 81 74
Mangia (Italy) 268 n/a† 58 n/a‡ 19 12–24 37 82 71
Sarrazin
(Germany)
205 46 54 n/a 30 24–48 42 87 71
Bochud
(Europe/Israel)
71 43 61 25 41 24–72 64 89 85
Moghaddam
(Europe)
281 38 59 n/a n/a 14–24 46 77 84
Fattovich (Italy) 159 46 55 25 24 24 39 92 90
Bitetto (Italy) 101 47 52 24 n/a 24 44 82 89
de Rueda (Spain) 50 n/a§ 58 n/a 23 48 50 84 80
Amanzada
(Germany)
47 49 77 n/a n/a 24–48 51 83 83
Halfon (France) 42 47 71 n/a 38 24 36 80 70
Lindh (Europe) 166 42 60 26 13 12–24 40 85 75
Total 1599 43 55% 24% 43% 83% 78%
Asian
Kawaoka (Japan) 130 57 56 23 17 24 82 78 67
Yu (Taiwan) 482 53 55 n/a 28 24 90 89 86
Sakamoto (Japan) 129 64 50 24 11 24 78 81 59
Sinn (Korea) 63 57 53 n/a 61 24 86 80 100
Ochi (Taiwan) 29 49 62 n/a n/a 24–48 90 92 33
Total 833 55 55% 22% 86% 86% 75%
SVR, sustained virologic response.
*Not all patients in each study underwent liver biopsy. In most studies, advanced fibrosis defined as Ishak score >4, META-
VIR score >3, or Scheur >F3. †78% of patients with age > 40 years. ‡42% of patients with BMI > 27 kg/m2. §62% of
patients with age > 40 years.
© 2013 John Wiley & Sons Ltd
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IL-28B genotype CC at rs12979860 (Table 1). Overall, 83%
of patients with the favourable IL-28B genotype achieved
SVR as compared to 78% of patients with the unfavourable
genotype, with a pooled OR of 1.36 (95%CI: 0.98–1.88,
P = 0.07) with low heterogeneity between studies
(I2 = 29%). In a subgroup analysis of eight studies that
included only treatment na€ıve patients, the pooled OR of SVR
was 1.21 (95%CI: 0.85–1.74, P = 0.29). Among the eight
studies with pegIFN and ribavirin treatment for at least
24 weeks, the pooled OR of SVR was 1.55 (95%CI: 1.10–
2.18, P = 0.01) as compared to 1.17 (95%CI: 0.53–2.58,
P = 0.70) in the studies with variable duration treatment reg-
imens. Among the four studies that used a ribavirin dose
800 mg/day for at least 24 weeks, the pooled OR of SVR
was 1.02 (95%CI: 0.55–1.92, P = 0.95). The pooled OR was
1.49 (95%CI: 1.02–2.19, P = 0.04) in the six high-quality
studies vs 1.33 (95%CI: 0.72–2.43, P = 0.36) in the five low-
quality studies (Table 2).
RVR outcome
Six studies reported RVR data in 1265 Caucasian patients
of which 42% had the favourable IL-28B genotype. Sev-
enty-seven percent of patients with the favourable IL-28B
achieved RVR as compared to 65% of patients with the
unfavourable genotype, with a pooled OR of 1.82 (95%CI:
1.12–2.96, P = 0.02) and moderate heterogeneity between
studies (I2 = 69%).
Among 350 patients who achieved RVR in three studies,
89% of 142 patients with the favourable IL-28B genotype
and 85% of 208 patients with the unfavourable IL-28B
genotype also achieved SVR (pooled OR: 1.37, 95%CI:
0.71–2.67, P = 0.35). In contrast, among 184 patients
who did not achieve RVR, 78% of 68 patients with the
favourable IL-28B and 50% of the 116 with the unfavour-
able IL-28B genotype achieved SVR (pooled OR: 3.29, 95%
CI: 1.67–6.51, P = 0.001).
Asians with HCV genotype 2
SVR outcome
There were five studies [20–24] of 833 Asian patients with
HCV genotype 2 infection, in which 86% had the favour-
able IL-28B genotype. Overall, 86% of patients with the
favourable IL-28B genotype achieved SVR, while 75% of
patients with the unfavourable IL-28B genotype achieved
SVR with a pooled OR of 1.99 (95%CI: 0.94–4.25,
P = 0.07). There was low to moderate heterogeneity
between studies (I2 = 44%). In a subgroup analysis of the
two studies that explicitly included only treatment na€ıve
patients, the pooled OR of SVR was 1.54 (95%CI: 0.81–
2.93, P = 0.18). Among the four low-quality studies, the
pooled OR was 2.22 (95%CI: 01.14–4.35, P = 0.02).
RVR outcome
In the two studies reporting RVR data, 88% of the 594
patients had the favourable IL-28B genotype. Eighty-two
percent of patients with the favourable IL-28B genotype
and 62% of patients with the unfavourable genotype
achieved RVR, with a pooled OR of RVR of 2.39 (95%CI:
1.39–4.11, P = 0.002).
Pooled analysis
After combining the 16 studies with 2432 patients, the
pooled OR of SVR in patients with the favourable IL-28B
genotype was 1.48 (95%CI: 1.09–2.02, P = 0.01). There
(a)
(b)Fig. 2 Forest plots of IL-28B genotype
and SVR in patients with hepatitis C
virus (HCV) genotype 2/3 infection
stratified by race. (A) There were 11
studies of 1599 Caucasian HCV
genotype 2/3 patientsm and (B) there
were five studies of 833 Asian HCV
genotype 2 patients. SVR, sustained
virologic response.
© 2013 John Wiley & Sons Ltd
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was low heterogeneity between studies (I2 = 34%). The
pooled OR was 1.27 (95%CI: 0.95–1.69, P = 0.11) in the
10 studies with only treatment na€ıve patients and 1.44
(95%CI: 0.98–2.11, P = 0.06) among the seven high-qual-
ity studies. There was no evidence of publication bias by
the Harbord or Peters tests (P = 0.69 and P = 0.33,
respectively).
DISCUSSION
While IL-28B genotyping has an important role in HCV
genotype 1 patients treated with pegIFN and ribavirin, its
value in HCV patients with genotype 2/3 remains less clear
[2]. This meta-analysis demonstrates that the favourable
IL-28B genotype is a significant predictor of SVR in Cauca-
sian patients with HCV genotype 2/3 treated with pegIFN
and ribavirin for 24 weeks. Additionally, IL-28B genotype
may be predictive of SVR in Asian patients with HCV geno-
type 2, although the pooled OR of SVR did not reach sta-
tistical significance perhaps due to inadequate sample size
(Fig. 2).
Our results also suggest that the favourable IL-28B geno-
type increases the odds of achieving RVR in Caucasian and
Asian patients with HCV genotype 2/3 infection, a finding
similar to that reported in HCV genotype 1 patients [2]. Fur-
thermore, the results of this study demonstrate that IL-28B
genotype may be helpful in stratifying the odds of SVR in
patients with HCV genotype 2/3 who do not achieve RVR.
Prior data suggest that HCV genotype 2/3 patients with
low viral load who achieve RVR may be candidates for a
shortened duration of therapy to 12–16 weeks [25,26].
However, it is unclear whether the favourable IL-28B geno-
type can be used to further identify patients from this group
who are more likely to achieve SVR and/or are at lower risk
of relapse. Individual studies have not found an association
between IL-28B genotype and SVR rates in patients treated
for <24 weeks after achieving RVR, but they may be under-
powered [13,19]. Therefore, IL-28B testing may play an
important role in counselling individual patients that are
receiving antiviral therapy and particularly in those experi-
encing side effects who do not achieve RVR.
In the era of DAAs, IL-28B testing in HCV genotype 1
patients may be limited to specific populations in which
DAAs are not yet approved, such as in those with HIV co-
infection [2]. In contrast, pegIFN and ribavirin are the only
currently approved agents for HCV genotype 2/3 infection.
An improved ability to predict SVR may be particularly
important for patients intolerant to this regimen, but the
absolute difference in response rates in those with and
without the favourable IL28-B genotype is small.
In contrast to our results, another recent meta-analy-
sis of IL-28B testing and SVR in patients of combined
HCV genotypes reports a statistically significant pooled
OR of SVR in Asians with HCV genotype 2 infection [5],
a finding likely due to the inclusion of only two Asian
studies. Our own subgroup analysis of five Asian studies
identified a strong trend which does not reach statistical
significance. The meta-analysis by Chen et al. also
demonstrates a lack of association between the favour-
able IL-28B genotype and SVR in Caucasian patients
with HCV genotype 2/3, although only five studies
were included. Assessing the role of IL-28B testing in
nonCaucasian patients with HCV genotype 2/3 was lim-
ited in our study. Among the five pooled Asian studies,
two explicitly included some treatment-experienced
patients who may have reduced the impact of IL-28B
genotyping in predicting SVR. In addition, there were no
studies of HCV genotype 2/3 African American patients,
a group with traditionally lower response to interferon.
However, a substantially lower proportion of African
Americans are infected with HCV genotype 2/3 in the
general US population compared to Caucasians (i.e. 5%
vs 20–30%) [27,28]. Because of the lack of stratification
by HCV genotype in many studies, we were unable to
determine whether IL-28B genotype has greater utility
in patients with HCV genotype 2 vs 3. However, this
issue is worthy of further study because HCV genotype 3
patients with a high baseline HCV RNA level are more
prone to relapse after a 24-week course of treatment
compared to those with HCV genotype 3 and low viral
load or HCV genotype 2 infection [29]. Finally, how IL-
28B testing fits in with other known pretreatment pre-
dictors of SVR remains unknown.
In conclusion, this meta-analysis demonstrates that the
favourable IL-28B genotype is significantly associated with
SVR in Caucasian patients with HCV genotype 2/3 infec-
tion treated with pegIFN and ribavirin for 24 weeks. How-
ever, the magnitude of the absolute difference in SVR rates
(83% vs 78%) is small and may not influence the decision
to initiate treatment. In addition, the favourable IL-28B
genotype is associated with RVR as well as SVR in patients
who do not achieve RVR, and this information may prove
useful to clinicians when counselling individual patients
during therapy.
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